Table 5 The sensitivity and specificity of combined IFITM1,CD10, h-caldesmon and SMA immunostaining in the diagnosis of cellular leiomyoma
Groups | Sensitivity (%) | Specificity (%) |
|---|---|---|
h-caldesmon (+) and IFITM1 (−) for CL | 69.7 | 100.0 |
SMA (+) and IFITM1 (−) for CL | 81.8 | 93.1 |
h-caldesmon (+) and CD10 (−) for CL | 72.7 | 96.6 |
SMA (+) and CD10 (−) for CL | 78.8 | 82.8 |
h-caldesmon (+) and SMA (+) for CL | 87.9 | 100.0 |
h-caldesmon (+) or SMA (+) for CL | 100.0 | 57.1 |
h-caldesmon (+) and SMA (+) and IFITM1 (−) for CL | 69.7 | 100.0 |
h-caldesmon (+) or SMA (+) and IFITM1 (−) for CL | 81.8 | 93.1 |
h-caldesmon (+) and SMA (+) and CD10 (−) for CL | 72.7 | 96.6 |
h-caldesmon (+) or SMA (+) and CD1 (−) for CL | 78.8 | 82.8 |
h-caldesmon (+) and SMA (+) and IFITM1 (−) and CD10 (−) for CL | 57.6 | 100.0 |
h-caldesmon (+) or SMA (+) and IFITM1 (−) and CD10 (−) for CL | 66.7 | 93.1 |